TNFRSF1B and neoplasm: Furthermore, once TNFR2-PLGA-ADR reaches the tumor site, TNFR2 antagonist antibodies can eliminate the immunosuppressive activity of Tregs, acting with ADR synergistically to enhance the anticancer effect.